TGFB1 and breast carcinoma: A phase Ib trial of NIS793 (a human anti-TGF-β1 IgG2 mAb) in combination with a checkpoint inhibitor spartalizumab, showed preliminary activity, and the regimen was well tolerated in patients with advanced solid tumors, including breast cancer (NCT02947165) [59].